Elevance Health (ELV) Stock Forecast & Price Target

$527.54

+13.51 (+2.63%)

(As of 07/26/2024 ET)

Elevance Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for Elevance Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 1 has given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ELV.

Consensus Price Target

$604.29
14.55% Upside

High Forecast	$649.00
Average Forecast	$604.29
Low Forecast	$530.00

According to the 15 analysts' twelve-month price targets for Elevance Health, the average price target is $604.29. The highest price target for ELV is $649.00, while the lowest price target for ELV is $530.00. The average price target represents a forecasted upside of 14.55% from the current price of $527.54.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$604.29	$611.36	$587.42	$568.93
Forecasted Upside	14.55% Upside	16.68% Upside	15.85% Upside	20.52% Upside

Get Elevance Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ELV and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

ELV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ELV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Elevance Health Stock vs. The Competition

Type	Elevance Health	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.45% Upside	2,880.85% Upside	9.52% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/23/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$600.00 ➝ $600.00	+19.09%
7/22/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$600.00 ➝ $593.00	+18.60%
7/19/2024	TD Cowen 4 of 5 stars		Lower Target	Buy ➝ Buy	$624.00 ➝ $589.00	+16.60%
7/18/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$621.00 ➝ $611.00	+21.70%
7/18/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$575.00 ➝ $585.00	+16.17%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$646.00 ➝ $530.00	+1.89%
Get the Latest News and Ratings for ELV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Elevance Health and its competitors with MarketBeat's FREE daily newsletter.
7/15/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$600.00 ➝ $620.00	+14.90%
6/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$643.00	+20.32%
6/11/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$615.00 ➝ $615.00	+14.69%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$628.00 ➝ $631.00	+24.00%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$649.00	+28.38%
4/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$575.00 ➝ $585.00	+9.77%
4/19/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$585.00 ➝ $605.00	+13.75%
4/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$602.00 ➝ $604.00	+15.01%
7/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
4/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/21/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$565.00 ➝ $550.00	+20.90%
4/20/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$571.00 ➝ $575.00	+25.73%
1/26/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$580.00	+17.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:22 PM ET.

ELV Forecast - Frequently Asked Questions

What is Elevance Health's forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevance Health is $604.29, with a high forecast of $649.00 and a low forecast of $530.00.
Should I buy or sell Elevance Health stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevance Health in the last twelve months. There is currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELV shares.
Does Elevance Health's stock price have much upside?: According to analysts, Elevance Health's stock has a predicted upside of 16.70% based on their 12-month stock forecasts.
Has Elevance Health been upgraded by Wall Street analysts recently?: Over the previous 90 days, Elevance Health's stock had 1 upgrade by analysts.
What analysts cover Elevance Health?: Elevance Health has been rated by research analysts at Baird R W, Bank of America, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stephens, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Elevance Health more than its competitors?: Analysts like Elevance Health more than other "medical" companies. The consensus rating for Elevance Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ELV compares to other companies.